FDA approves Roche?s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
- Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administration
- Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration